Low immunoglobulin levels affect nearly 1 in 4 newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) and significantly increase infection risk during treatment. Patients with low ...

Commercialization of Gammagard Liquid ERC is expected to begin in 2026. The Food and Drug Administration (FDA) has approved Gammagard Liquid ERC (immune globulin infusion [human] 10% solution) as a ...

“The approval of GAMMAGARD LIQUID ERC reinforces our commitment to supporting individualized treatment approaches for people with primary immunodeficiency, including a therapeutic option that has the ...

Please provide your email address to receive an email when new articles are posted on . A prototype point-of-care rapid screening device differentiated between low immunoglobulin G antibody levels ...

(WASHINGTON, June 21, 2024) – Patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas (NHLs) who received frequent tests for immunoglobulin G (IgG) were less likely to experience ...

Many patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma do not undergo immunoglobulin G testing despite its potential to reduce likelihood of severe infections. Blood cancers increase ...

Patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas (NHLs) who received frequent tests for immunoglobulin G (IgG) were less likely to experience severe infections compared with ...

The patient continued to test positive for COVID-19, but intravenous immunoglobulin eventually led to his recovery. People with chronic lymphocytic leukemia (CLL) are at a higher risk of contracting ...

A team of scientists from the Chinese Academy of Sciences (CAS) and BGI Research has uncovered the intricate mechanisms by which immunoglobulins influence the aging process, a finding that might ...

GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with Less Than or Equal to 2 µg/mL IgA in a 10% Solution is Approved for Intravenous or Subcutaneous Use in People Aged Two and Older with ...